From the Reuters:
Sales in China for drugs to treat hypertension are expected to nearly double to more than $800 million by 2010 amid higher awareness of the disease and as more Chinese are exposed to risk factors such as obesity, a U.S. research firm said.
The Chinese market for blood pressure treatment drugs, such as Pfizer Inc.’s Norvasc and Novartis AG’s Diovan, was worth about $440 million last year, roughly 4 percent of the U.S. market, market research firm Decision Resources said in a report released on Tuesday.
Diagnosis rates for hypertension will rise to 41 percent in 2010 from 33 percent last year, boosted by Beijing’s health education efforts, the firm said. [Full Text]
Related article of “Increasing number of Chinese youngsters suffer hypertension” from Xinhua
Another article of “China Adds 3 Million Hypertension Patients a Year” from People’s Daily
